Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568453 | 0.81 | KDM4E (0.58) | KDM4EALDH1A1MAPTSMN1; SMN2HPGD | |
| SCHEMBL31019369 | 0.78 | KDM4E (0.47) | KDM4ECRBNALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL9093659 | 0.74 | KDM4E (0.46) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL9739665 | 0.71 | KDM4E (0.60) | KDM4ECRBNACHEALDH1A1CYP1A2 | |
| SCHEMBL1759498 | 0.71 | KDM4E (0.42) | KDM4EALDH1A1CYP1A2CYP2C19LMNA | |
| SCHEMBL29433775 | 0.69 | CA9 (0.47) | KDM4EALDH1A1CYP1A2CYP2C19LMNA | |
| SCHEMBL9092910 | 0.69 | CA9 (0.47) | KDM4EALDH1A1CYP1A2CYP2C19LMNA | |
| SCHEMBL2061212 | 0.69 | CA9 (0.44) | KDM4ECRBNALDH1A1LMNAMAPT | |
| SCHEMBL12079122 | 0.69 | PARP10 (0.46) | KDM4ECRBNMAPT | |
| Noroxyhydrastinine SCHEMBL564339 | 0.68 | KDM4E (1.00) | KDM4EACHECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765728-B2 | [1,5]-diazocin derivatives | MELLITECH (FR) | 2014-07-01 | — | — | US | disclosed |
| EP-2501685-A1 | [1,5]-DIAZOCIN DERIVATIVES | Mellitech (FR) | 2012-09-26 | — | — | EP | disclosed |
| US-20120225892-A1 | [1,5]-Diazocin Derivatives | MELLITECH (FR) | 2012-09-06 | — | — | US | disclosed |
| WO-2011058193-A1 | [1,5]-DIAZOCIN DERIVATIVES | MELLITECH (FR) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225892-A1 | [1,5]-Diazocin Derivatives | IAPP, INSR, GLP1R | KDM4E 3585/4885CRBN 3374/4885ACHE 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.